LENZ Therapeutics is a company in the advanced stages of clinical development, focused on creating pioneering pharmaceutical products for eye care. The organization's primary effort involves an aceclidine-based eye drop intended to address the decline in near vision associated with presbyopia, a condition affecting nearly two billion individuals worldwide and over 120 million in the US. Situated in San Diego, California, LENZ Therapeutics benefits from the support of prominent venture capital investors.
Lenz Therapeutics
Headquarters
United States of America